Abstract: An HSV vector comprising an expression cassette for one or more of IL12, IL15, and hIL15Receptor alpha subunit is provided.

Abstract: An HSV vector comprising an expression cassette for one or more of IL12, IL15, and hIL15Receptor alpha subunit is provided.

Abstract: An oncolytic HSV vector comprising an NF-?B response element or an Oct-3/4-SOX2 response element in a regulatory region of a viral gene that affects viral replication efficiency.

Abstract: Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.

Abstract: The present disclosure relates to the use of an oncolytic virus, such as HSV, and a STAT1/3 inhibitor, such as nifuroxazide and C16, in the treatment of cancer. Therapeutic compositions are provided that may be used to prevent, treat, or ameliorate the effects of a targeted cancer. Methods of using such compositions are also disclosed, such as methods of using the therapeutic compositions for improving efficacy of an oncolytic virotherapy (and for preventing macrophage and microglia inhibition of oncolytic viral activity).

Abstract: Compositions and methods are provided for treating cancer comprising a composition comprising an oncolytic virus and a targeting moiety on the surface of the virus, wherein the oncolytic virus does not encode or express the targeting moiety within various aspects such compositions and methods can be used to treat a wide variety of cancers (e.g., gastrointestinal cancer, such as esophageal, stomach and colon cancers).

Abstract: Vaccines are provided comprising a recombinant virus which expresses an immunomodulatory protein and a target antigen unrelated to said recombinant virus, and a pharmaceutically acceptable excipient.

Abstract: Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.

Abstract: Recombinant herpes simplex viruses are provided having a modified oncolytic herpes virus genome, wherein the modified herpes virus genome has at least one miRNA target sequence operably linked to a first or to a first and a second copy of an ICP34.5 gene. Also provided are pharmaceutical compositions having such recombinant herpes simplex viruses, as well as methods of using such compositions in the treatment of subjects having cancer.

Abstract: Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.

Abstract: The present disclosure relates to the use of an oncolytic virus, such as HSV, and a STAT1/3 inhibitor, such as nifuroxazide and C16, in the treatment of cancer. Therapeutic compositions are provided that may be used to prevent, treat, or ameliorate the effects of a targeted cancer. Methods of using such compositions are also disclosed, such as methods of using the therapeutic compositions for improving efficacy of an oncolytic virotherapy (and for preventing macrophage and microglia inhibition of oncolytic viral activity).

Abstract: An HSV vector comprising an expression cassette for one or more of IL12, IL15, and hIL15Receptor alpha subunit is provided.

Abstract: An oncolytic HSV vector comprising an NF-?B response element or an Oct-3/4-SOX2 response element in a regulatory region of a viral gene that affects viral replication efficiency.

Abstract: Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.

Abstract: Modified and improved oncolytic viruses (and methods of use thereof) are disclosed. More particularly, modified and oncolytic human herpesviruses (and methods of use thereof) are disclosed, which include a modified amino acid sequence that includes a deletion in a region that represents the amino terminus of glycoprotein K. The modified and oncolytic human herpesviruses include a deletion of amino acid residues 31-68, relative to the wild type amino acid sequence of glycoprotein K in human herpesviruses. Isolated vector constructs that encode such oncolytic viruses are also disclosed. In addition, methods for using such oncolytic viruses to treat cancers are disclosed.

Abstract: The invention provides for the use of ginsenoside Rh2 in pharmaceutical compositions used in methods of inhibiting the multiplication of cancer cells, and methods of treating cancer in patients, comprising administering to such patients therapeutically and synergistically effective amounts of Rh2 in combination with a chemotherapeutic selected from the group consisting of paclitaxel and mitoxantrone. The cancer cells to be treated may be multidrug resistant. The cancer cells may for example be prostate cancer cells or breast cancer cells.

Abstract: The invention provides for the use of ginsenoside Rh2 in pharmaceutical compositions used in methods of inhibiting the multiplication of cancer cells, and methods of treating cancer in patients, comprising administering to such patients therapeutically and synergistically effective amounts of Rh2 in combination with a chemotherapeutic selected from the group consisting of paclitaxel and mitoxantrone. The cancer cells to be treated may be multidrug resistant. The cancer cells may for example be prostate cancer cells or breast cancer cells.